Medication Comparison · Updated November 2026

Mounjaro vs Zepbound: Same Drug, Different Label

Mounjaro and Zepbound are the exact same molecule: tirzepatide, made by Eli Lilly. Same dose strengths, same manufacturer, and the same presentations on both labels. The only real differences are the FDA indication on the label, how your insurance company treats them, and what your doctor writes on the prescription. Here is what actually matters when choosing between them.

The Short Version

• Mounjaro and Zepbound contain the same drug: tirzepatide. Same manufacturer (Eli Lilly) and same doses (2.5 to 15 mg). Both Mounjaro and Zepbound labels list single-dose pens and vials, multi-dose vials and KwikPens.
• Mounjaro is FDA-approved for type 2 diabetes (approved 2022). Zepbound is FDA-approved for weight management (approved 2023) and for obstructive sleep apnea in adults with obesity.
• Insurance coverage is the main practical difference. Mounjaro is on more formularies because diabetes medications get broader coverage. Zepbound (weight management) faces more coverage exclusions.
• Self-pay prices differ. Lilly lists the Zepbound KwikPen at $299 to $449/mo self-pay, and the Mounjaro pen as low as $499/mo with its savings card when insurance does not cover it (checked Nov 4, 2026).
• If you have type 2 diabetes, Mounjaro is the easier path. If your only goal is weight loss and you do not have diabetes, Zepbound is the on-label choice. My type 2 diabetes vs weight loss guide covers the same split for Ozempic and Wegovy.

Quick Comparison Table

The Same Drug, Literally

I want to be very clear about this: Mounjaro and Zepbound are not “similar” drugs. They are the exact same drug. Eli Lilly manufactures both using the same active ingredient (tirzepatide) and the same dose strengths. The labels and boxes differ.

I have been on Mounjaro for over a year. If my prescriber switched me to Zepbound tomorrow, the medication going into my body would be identical. The molecule does not know what the box says.

So why do two versions exist?

Why Two Brand Names?

Pharmaceutical companies often sell the same molecule under different names for different indications. It is a regulatory and commercial strategy.

Mounjaro went through the FDA approval process for type 2 diabetes. The clinical trials (SURPASS program) measured A1C reduction as the primary endpoint. Weight loss was a secondary finding. Approved May 13, 2022.

Zepbound went through a separate FDA approval for chronic weight management. The clinical trials (SURMOUNT program) measured percent body weight lost as the primary endpoint. Approved November 8, 2023. A sleep apnea indication was added later.

The reason this matters: the FDA indication determines how insurance companies classify the drug. Diabetes medications and weight management medications sit on different parts of the formulary. They have different coverage rules, different prior authorization requirements, and different copay structures.

Weight Loss: Identical Results

Since the molecule is the same, the weight loss results are the same. The SURMOUNT-1 trial (which supported Zepbound’s approval) showed:

• 5 mg dose: 15.0% body weight loss
• 10 mg dose: 19.5% body weight loss
• 15 mg dose: 20.9% body weight loss

The SURPASS trials (which supported Mounjaro’s approval) focused on people with type 2 diabetes, who tend to lose less weight. In SURPASS-2, tirzepatide 5, 10 and 15 mg lowered weight by 1.9, 3.6 and 5.5 kg more than semaglutide 1 mg over 40 weeks.

In the head-to-head SURMOUNT-5 trial, tirzepatide (the molecule in both drugs) produced 20.2% weight loss versus 13.7% for semaglutide. Whether your pen says “Mounjaro” or “Zepbound” on the label does not change this.

Side Effects: Identical

Same molecule, same side effects. The most common are gastrointestinal. In the Zepbound weight-loss trials, the label reports nausea in 25% to 29% of patients across doses, diarrhea in 19% to 23%, constipation in 11% to 17% and vomiting in 8% to 13%. These are typically worst during dose escalation (the first 1-2 weeks at each new dose) and tend to fade.

From personal experience on Mounjaro: the nausea at each dose increase was real but manageable. Smaller meals, avoiding fatty foods, and staying hydrated made the biggest difference. By 15 mg (my current dose), I rarely notice any GI issues. Full details in our side effects guide.

Cost Comparison

For cash payers, Zepbound is cheaper. For insured patients, the difference comes down to coverage. Savings cards end December 31, 2026, and exclude Medicare, Medicaid and other government plans.

Mounjaro savings path: If you have type 2 diabetes and commercial insurance that covers Mounjaro, Lilly’s savings card can bring your copay as low as $25/month. This is the cheapest legitimate way to get tirzepatide.

Zepbound savings path: Lilly sells the Zepbound KwikPen self-pay at $299 (2.5 mg), $399 (5 mg) and $449 (7.5 to 15 mg, with a refill within 45 days) per month. No insurance required. This is useful if your insurance does not cover weight management drugs.

For most people, the question is simple: which one will your insurance actually cover? For a full pricing comparison across all options, see our cheapest GLP-1 online guide.

Insurance Coverage: Where It Actually Matters

This is the section that determines which drug most people end up on.

Mounjaro Coverage (Diabetes)

Many commercial plans and Medicare Part D formularies cover Mounjaro for type 2 diabetes. You may need a prior authorization.

The catch: If you want Mounjaro for weight loss and do not have diabetes, your prescriber would be writing it off-label. Some insurers will cover off-label Mounjaro for weight management, but many will not. You may get denied and need to appeal.

Zepbound Coverage (Weight Management)

Zepbound coverage is growing but still limited. Many employer plans explicitly exclude anti-obesity medications. Some large employers and state programs have started adding coverage, but it is far from universal.

The catch: Even though Zepbound is the on-label option for weight loss, fewer insurance plans cover weight management drugs than diabetes drugs. This is the core irony of the Mounjaro vs Zepbound decision.

Medicare

Medicare Part D does not cover drugs used only for weight loss. If you have type 2 diabetes, Medicare may cover Mounjaro for that indication. Coverage for Zepbound’s sleep apnea indication depends on your plan. See our GLP-1 Medicare coverage guide for the latest.

What Your Doctor Can Do

Your prescriber plays a significant role here. If you have type 2 diabetes, your doctor can prescribe Mounjaro on-label, and weight loss is an expected effect. Prediabetes is not a Mounjaro indication.

If you do not have diabetes, your doctor will likely prescribe Zepbound (on-label for weight management) and help you navigate the prior authorization process. For details on navigating the insurance maze, see our GLP-1 insurance coverage guide.

Choose Mounjaro If…

• You have type 2 diabetes. Mounjaro is the on-label choice, and insurance coverage is much broader. Prediabetes is not a Mounjaro indication, so ask your doctor whether Zepbound fits instead.
• Your insurance covers it for diabetes. With the savings card, you could pay as little as $25/month.
• Your prescriber recommends it for your metabolic condition. In SURPASS-2, tirzepatide lowered A1C by 2.01 to 2.30 percentage points over 40 weeks.

Choose Zepbound If…

• You want weight loss and do not have diabetes. Zepbound is the FDA-approved option for weight management, which means your prescriber does not need to write it off-label.
• You are self-paying. Lilly’s $299 to $449/month KwikPen pricing makes Zepbound accessible without insurance.
• Your insurance covers weight management drugs. If your plan includes anti-obesity medications, Zepbound will be the on-label, easier-to-approve option.

The Compounded Alternative

If neither Mounjaro nor Zepbound is affordable through insurance, compounded tirzepatide is a third option. It is not FDA-approved, and its legal footing narrowed after FDA declared the tirzepatide shortage over.

FDA says the tirzepatide shortage was resolved in December 2024, and the grace periods ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. Today only 503A pharmacies may compound it, in narrow patient-specific cases. With Zepbound self-pay at $299 to $449, the savings are smaller than they used to be. See our compounded vs brand-name guide.

Frequently Asked Questions

Can I switch between Mounjaro and Zepbound?

Yes, and it is straightforward because they are the same drug. Your prescriber would write a new prescription for the other brand, usually at the same dose. Let your prescriber decide the dose. The most common reason to switch is a change in insurance coverage.

Is there any clinical difference between Mounjaro and Zepbound?

No. The molecule is identical. The clinical trials tested the same drug in different populations (diabetes patients for Mounjaro, overweight/obese patients without diabetes for Zepbound). The weight loss and side effects are the same.

Will insurance cover Mounjaro for weight loss if I do not have diabetes?

It depends on your specific plan. Some commercial insurers cover off-label Mounjaro for weight management. Many do not. Your prescriber would need to submit a prior authorization, and there is a real chance of denial. If denied, Zepbound (on-label for weight loss) or the appeal process are your next steps.

What if I cannot afford either brand?

Three options: (1) Apply for Lilly’s savings programs and see if you qualify. (2) Check Zepbound KwikPen self-pay ($299 to $449/mo) or compounded tirzepatide, which is not FDA-approved. (3) Consider semaglutide products (Ozempic or Wegovy) if they are cheaper or better covered by your insurance. See our cheapest GLP-1 online guide for a full comparison.

Do pharmacies treat Mounjaro and Zepbound the same?

No. Pharmacies process them as separate products with different NDC codes and different insurance billing. Even though the molecule is identical, your pharmacy will dispense whichever one your prescriber specifically wrote on the prescription. You cannot swap one for the other at the pharmacy counter the way you can with a generic substitution.

Last updated: November 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed the Mounjaro and Zepbound prescribing information, FDA approval records and compounding policy, the SURMOUNT-1, SURMOUNT-5 and SURPASS-2 trial publications, and Lilly’s Mounjaro and Zepbound savings pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.